Novonesis (Novozymes) A/S (NSIS-B) - Total Assets
Based on the latest financial reports, Novonesis (Novozymes) A/S (NSIS-B) holds total assets worth Dkr16.30 Billion DKK (≈ $2.55 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Novonesis (Novozymes) A/S's book value for net asset value and shareholders' equity analysis.
Novonesis (Novozymes) A/S - Total Assets Trend (2002–2024)
This chart illustrates how Novonesis (Novozymes) A/S's total assets have evolved over time, based on quarterly financial data.
Novonesis (Novozymes) A/S - Asset Composition Analysis
Current Asset Composition (December 2024)
Novonesis (Novozymes) A/S's total assets of Dkr16.30 Billion consist of 12.4% current assets and 87.6% non-current assets.
| Asset Category | Amount (DKK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 1.8% |
| Accounts Receivable | Dkr804.60 Million | 5.3% |
| Inventory | Dkr720.60 Million | 4.7% |
| Property, Plant & Equipment | Dkr0.00 | 0.0% |
| Intangible Assets | Dkr4.42 Billion | 29.1% |
| Goodwill | Dkr5.61 Billion | 36.9% |
Asset Composition Trend (2002–2024)
This chart illustrates how Novonesis (Novozymes) A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Novonesis (Novozymes) A/S worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Novonesis (Novozymes) A/S's current assets represent 12.4% of total assets in 2024, a decrease from 45.2% in 2002.
- Cash Position: Cash and equivalents constituted 1.8% of total assets in 2024, down from 10.0% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 65.0% of total assets, an increase from 6.0% in 2002.
- Asset Diversification: The largest asset category is goodwill at 36.9% of total assets.
Novonesis (Novozymes) A/S Competitors by Total Assets
Key competitors of Novonesis (Novozymes) A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Air Products and Chemicals Inc
NYSE:APD
|
USA | $41.24 Billion |
|
AKZO NOBEL SPONS.ADRS 1/3
F:AKUP
|
Germany | €13.95 Billion |
|
Kingfa Sci&Tech Co Ltd
SHG:600143
|
China | CN¥63.79 Billion |
|
Zhongfu Shenying Carbon Fiber Co. Ltd. A
SHG:688295
|
China | CN¥9.37 Billion |
|
Arkema SA
PA:AKE
|
France | €14.30 Billion |
|
Baoding Lucky Innovative Materials Co Ltd
SHE:300446
|
China | CN¥11.49 Billion |
|
Yibin Tianyuan Group Co Ltd
SHE:002386
|
China | CN¥19.28 Billion |
|
Longkou Union Chemical Co. Ltd. A
SHE:301209
|
China | CN¥968.45 Million |
Novonesis (Novozymes) A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.61 | 1.73 | 1.66 |
| Quick Ratio | 1.00 | 1.06 | 1.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Dkr744.00 Million | Dkr5.90 Billion | Dkr2.75 Billion |
Novonesis (Novozymes) A/S - Advanced Valuation Insights
This section examines the relationship between Novonesis (Novozymes) A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.32 |
| Latest Market Cap to Assets Ratio | 1.61 |
| Asset Growth Rate (YoY) | -46.5% |
| Total Assets | Dkr15.20 Billion |
| Market Capitalization | $24.39 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Novonesis (Novozymes) A/S's assets above their book value (1.61x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Novonesis (Novozymes) A/S's assets decreased by 46.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Novonesis (Novozymes) A/S (2002–2024)
The table below shows the annual total assets of Novonesis (Novozymes) A/S from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Dkr15.20 Billion ≈ $2.38 Billion |
-46.48% |
| 2023-12-31 | Dkr28.39 Billion ≈ $4.44 Billion |
+1.46% |
| 2022-12-31 | Dkr27.98 Billion ≈ $4.38 Billion |
+12.99% |
| 2021-12-31 | Dkr24.77 Billion ≈ $3.87 Billion |
+20.76% |
| 2020-12-31 | Dkr20.51 Billion ≈ $3.21 Billion |
+0.36% |
| 2019-12-31 | Dkr20.44 Billion ≈ $3.20 Billion |
+3.76% |
| 2018-12-31 | Dkr19.70 Billion ≈ $3.08 Billion |
+7.21% |
| 2017-12-31 | Dkr18.37 Billion ≈ $2.87 Billion |
-1.53% |
| 2016-12-31 | Dkr18.66 Billion ≈ $2.92 Billion |
+4.88% |
| 2015-12-31 | Dkr17.79 Billion ≈ $2.78 Billion |
-3.45% |
| 2014-12-31 | Dkr18.43 Billion ≈ $2.88 Billion |
+11.63% |
| 2013-12-31 | Dkr16.51 Billion ≈ $2.58 Billion |
+9.22% |
| 2012-12-31 | Dkr15.11 Billion ≈ $2.36 Billion |
+9.18% |
| 2011-12-31 | Dkr13.84 Billion ≈ $2.17 Billion |
+9.92% |
| 2010-12-31 | Dkr12.59 Billion ≈ $1.97 Billion |
+15.64% |
| 2009-12-31 | Dkr10.89 Billion ≈ $1.70 Billion |
+9.72% |
| 2008-12-31 | Dkr9.93 Billion ≈ $1.55 Billion |
+11.88% |
| 2007-12-31 | Dkr8.87 Billion ≈ $1.39 Billion |
+11.37% |
| 2006-12-31 | Dkr7.96 Billion ≈ $1.25 Billion |
+8.98% |
| 2005-12-31 | Dkr7.31 Billion ≈ $1.14 Billion |
+2.45% |
| 2004-12-31 | Dkr7.13 Billion ≈ $1.12 Billion |
-6.54% |
| 2003-12-31 | Dkr7.63 Billion ≈ $1.19 Billion |
-8.59% |
| 2002-12-31 | Dkr8.35 Billion ≈ $1.31 Billion |
-- |
About Novonesis (Novozymes) A/S
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as protein solutions and … Read more